Bio-Rad Reports Steep Q1 Net Loss of $527.1M, EPS Plunges to ($19.55)
BIO sits 32% above its 52-week low of $211.43 on elevated volume (2.1× avg).
Summary
Bio-Rad Laboratories reported a significant net loss of ($527.1M) and diluted EPS of ($19.55) for the first quarter of 2026, a sharp deterioration from a net income of $64M and EPS of $2.29 in the prior-year quarter. While net sales nominally increased by 1.1% to $592.1M, currency-neutral sales declined by approximately 4.2%, indicating underlying demand weakness. This substantial swing to a loss, driven by charges, higher material and logistics costs, inventory scrap, and restructuring, signals significant operational challenges. The results contrast sharply with the full-year 2025 net income, which was largely bolstered by a non-operating gain. Traders will likely react negatively to these results, given the material impact on profitability and the cited headwinds from government spending constraints and geopolitical uncertainties.
At the time of this announcement, BIO was trading at $280.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $211.43 to $343.12. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.